Key facts
- Antigenix Therapeutics’s last known valuation is $15.0M (Dec 2025).
- It has raised $7.0M across 1 recorded rounds; the latest was Seed Round ($3.4M) in Oct 2025.
- Notable investors include New Jersey Economic Development Authority, Pier 70 Ventures, Syridex Bio.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Antigenix Therapeutics
Funding rounds
1 roundsAbout Antigenix Therapeutics
Developer of a platform designed to create antibody-based therapies that precisely target cancer cells while sparing healthy tissue. The company offers monoclonal antibodies directed at novel, tumor-specific targets, enabling cancer patients with high unmet needs to receive safer and more effective treatment options.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2024
- Employees
- 4
- Website
- antigenixthera.com/
- Ownership
- Privately Held (backing)
Antigenix Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Antigenix Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Antigenix Therapeutics in its N-PORT filings yet. We sweep new filings monthly.